一种识别前列腺癌扩大盆腔淋巴结清扫候选者的新模型的开发与内部验证
本研究纳入2011至2016年间接受根治性前列腺切除术和扩大盆腔淋巴结清扫的681例有详细活检信息的前列腺癌患者,构建并内部验证了一个预测淋巴结侵犯的列线图。模型包含前列腺特异性抗原、临床分期、活检Gleason分级分组、最高级别癌穿刺针百分比及低级别癌穿刺针百分比,交叉验证后预测准确度为90.8%。作者结论认为,对于详细活检信息且淋巴结侵犯风险低于7%的患者应避免扩大盆腔淋巴结清扫。
要点
- 新列线图预测淋巴结侵犯的交叉验证准确度为90.8%,高于Briganti(89.5%)和纪念斯隆凯特琳癌症中心(89.5%)列线图。
- 采用7%截点,可避免471例(69%)扩大盆腔淋巴结清扫,仅遗漏7例(1.5%)淋巴结侵犯。
- 作者结论认为,详细活检信息且淋巴结侵犯风险低于7%的患者应避免扩大盆腔淋巴结清扫。
核心结论
- 对于有详细活检信息且淋巴结侵犯风险低于7%的患者,应避免扩大盆腔淋巴结清扫,以约70%的扩大盆腔淋巴结清扫为代价,仅遗漏1.5%的淋巴结侵犯。
研究设计与样本
- 回顾性识别2011至2016年间接受根治性前列腺切除术和扩大盆腔淋巴结清扫的681例有详细活检信息的患者,活检由高容量泌尿病理学家评估。
- 拟合多变量逻辑回归模型预测淋巴结侵犯,并以此为基础构建基于系数的列线图。
- 使用受试者工作特征曲线下面积、校准图和决策曲线分析评估模型。
主要发现
- 中位切除淋巴结数为16枚,79例(12%)患者存在淋巴结侵犯。
- 多变量模型包含前列腺特异性抗原、临床分期、活检Gleason分级分组、最高级别前列腺癌穿刺针百分比及低级别癌穿刺针百分比。
- 交叉验证后,这些预测因素在本队列中的预测准确度为90.8%。
- 决策曲线分析显示,在淋巴结侵犯阈值概率≤20%时,风险预测改善。
- 与Briganti和纪念斯隆凯特琳癌症中心列线图相比,新模型曲线下面积更高(90.8% vs 89.5% vs 89.5%),校准特性更好,决策曲线分析净获益更高。
关键数值与推荐
- 采用7%截点,可避免471例(69%)扩大盆腔淋巴结清扫,遗漏7例(1.5%)淋巴结侵犯。
临床怎么用
- 作者结论认为,有详细活检信息且淋巴结侵犯风险低于7%的患者应避免扩大盆腔淋巴结清扫。
- 作者指出,根据该模型仅对淋巴结侵犯风险>7%的男性进行淋巴结清扫,可显著减少不必要的盆腔淋巴结清扫,仅遗漏1.5%的淋巴结侵犯患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preoperative assessment of the risk of lymph node invasion (LNI) is mandatory to identify prostate cancer (PCa) patients who should receive an extended pelvic lymph node dissection (ePLND). OBJECTIVE: To update a nomogram predicting LNI in contemporary PCa patients with detailed biopsy reports. DESIGN, SETTING, AND PARTICIPANTS: Overall, 681 patients with detailed biopsy information, evaluated by a high-volume uropathologist, treated with radical prostatectomy and ePLND between 2011 and 2016 were identified. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A multivariable logistic regression model predicting LNI was fitted and represented the basis for a coefficient-based nomogram. The model was evaluated using the receiver operating characteristic-derived area under the curve (AUC), calibration plot, and decision-curve analyses (DCAs). RESULTS AND LIMITATIONS: The median number of nodes removed was 16. Overall, 79 (12%) patients had LNI. A multivariable model that included prostate-specific antigen, clinical stage, biopsy Gleason grade group, percentage of cores with highest-grade PCa, and percentage of cores with lower-grade disease represented the basis for the nomogram. After cross validation, the predictive accuracy of these predictors in our cohort was 90.8% and the DCA demonstrated improved risk prediction against threshold probabilities of LNI ≤20%. Using a cutoff of 7%, 471 (69%) ePLNDs would be spared and LNI would be missed in seven (1.5%) patients. As compared with the Briganti and Memorial Sloan Kettering Cancer Center nomograms, the novel model showed higher AUC (90.8% vs 89.5% vs 89.5%), better calibration characteristics, and a higher net benefit at DCA. CONCLUSIONS: An ePLND should be avoided in patients with detailed biopsy information and a risk of nodal involvement below 7%, in order to spare approximately 70% ePLNDs at the cost of missing only 1.5% LNIs. PATIENT SUMMARY: We developed a novel nomogram to predict lymph node invasion (LNI) in patients with clinically localized prostate cancer based on detailed biopsy reports. A lymph node dissection exclusively in men with a risk of LNI >7% according to this model would significantly reduce the number of unnecessary pelvic nodal dissections with a risk of missing only 1.5% of patients with LNI.
引用
- Gandaglia G, Fossati N, Zaffuto E, et al. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. Eur Urol. 2017. PMID: 28412062. doi:10.1016/j.eururo.2017.03.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。